T Cell-mediated hypersensitivity reactions to drugs

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 439-454

  Pavlos, Rebecca ^a   Mallal, Simon ^a,b   Ostrov, David ^c   Buus, Soren ^d   Metushi, Imir ^e   Peters, Bjoern ^e   Phillips, Elizabeth ^a,b  

^a MURDOCH UNIVERSITY   (Australia)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

altered peptide; human leukocyte antigen; major histocompatibility complex; pharmacogenomics; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

ABACAVIR; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAMAZEPINE; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; NEVIRAPINE; OXIPURINOL; T LYMPHOCYTE RECEPTOR;

ALLELE; ALLERGIC REACTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DELAYED HYPERSENSITIVITY; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG METABOLISM; HAPLOTYPE; HUMAN; IMMUNOPATHOGENESIS; MOLECULAR DOCKING; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TISSUE SPECIFICITY; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; GENETICS; IMMUNOLOGY;

DRUG HYPERSENSITIVITY; DRUG HYPERSENSITIVITY SYNDROME; HLA ANTIGENS; HUMANS; HYPERSENSITIVITY, DELAYED; STEVENS-JOHNSON SYNDROME; T-LYMPHOCYTES;

EID: 84921415227     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050913-022745     Document Type: Article

References (80)

1. Gell PGH, Coombs RRA. 1963. The classification of allergic reactions underlying disease. In Clinical Aspects of Immunology, ed. RRA Coombs, PGH Gell, pp. 317-37. London: Blackwell Sci.
2. Pirmohamed M, Aithal GP, Behr E, et al. 2011. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin. Pharmacol. Ther. 89:784-85
3. Hung SI, Chung WH, Liou LB, et al. 2005. HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 102:4134-39
4. Somkrua R, Eickman EE, Saokaew S, et al. 2011. Association of HLA-B5801 allele and allopurinolinduced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-Analysis. BMC Med. Genet. 12:118
5. Zhang FR, Liu H, Irwanto A, et al. 2013. HLA-B13:01 and the dapsone hypersensitivity syndrome. N. Engl. J. Med. 369:1620-28
6. Daly AK, Donaldson PT, Bhatnagar P, et al. 2009. HLA-B5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41:816-19
7. Hetherington S, Hughes AR, Mosteller M, et al. 2002. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359:1121-22
8. Mallal S, Nolan D, Witt C, et al. 2002. Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-Transcriptase inhibitor abacavir. Lancet 359:727-32
9. ChungWH, Hung SI, Hong HS, et al. 2004. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486
10. Hung SI, Chung WH, Jee SH, et al. 2006. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16:297-306
11. McCormack M, Alfirevic A, Bourgeois S, et al. 2011. HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364:1134-43
12. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. 1999. HLA association of amoxicillinclavulanate-induced hepatitis. Gastroenterology 117:1181-86
13. Donaldson PT, Daly AK, Henderson J, et al. 2010. Human leucocyte antigen class II genotype in susceptibility and resistance to co-Amoxiclav-induced liver injury. J. Hepatol. 53:1049-53
14. O'Donohue J, OienKA, Donaldson P, et al. 2000. Co-Amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47:717-20
15. Martin AM, Nolan D, James I, et al. 2005. Predisposition to nevirapine hypersensitivity associated with HLA-DRB10101 and abrogated by low CD4 T-cell counts. AIDS 19:97-99
16. Yuan J, Guo S, Hall D, et al. 2011. Toxicogenomics of nevirapine-Associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 25:1271-80
17. Spraggs CF, Budde LR, Briley LP, et al. 2011. HLA-DQA102:01 is a major risk factor for lapatinibinduced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29:667-73
18. Spraggs CF, Parham LR, Hunt CM, Dollery CT. 2012. Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes. Clin. Pharmacol. Ther. 91:647-52
19. Singer JB, Lewitzky S, Leroy E, et al. 2010. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42:711-14
20. Keisu M, Andersson TB. 2010. Drug-induced liver injury in humans: the case of ximelagatran. Handb. Exp. Pharmacol. 196:407-18
21. Yvon M, Anglade P, Wal JM. 1990. Identification of the binding sites of benzyl penicilloyl, the allergenic metabolite of penicillin, on the serum albumin molecule. FEBS Lett. 263:237-40
22. Kelly JW, Dooley DP, Lattuada CP, Smith CE. 1992. A severe, unusual reaction to trimethoprimsulfamethoxazole in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 14:1034-39
23. PichlerWJ, Beeler A, KellerM, et al. 2006. Pharmacological interaction of drugs with immune receptors: the P-I concept. Allergol. Int. 55:17-25
24. Cutrell AG, Hernandez JE, Fleming JW, et al. 2004. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann. Pharmacother. 38:2171-72
25. Rauch A, Nolan D, Thurnheer C, et al. 2008. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir. Ther. 13:1019-28
26. Saag M, Balu R, Phillips E, et al. 2008. High sensitivity of human leukocyte antigen-B5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46:1111-18
27. Mallal S, Phillips E, Carosi G, et al. 2008. HLA-B5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358:568-79
28. Martin AM, Nolan D, Gaudieri S, et al. 2004. Predisposition to abacavir hypersensitivity conferred by HLA-B5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. USA 101:4180-85
29. Rauch A, Nolan D, Martin A, et al. 2006. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in theWestern Australian HIV cohort study. Clin. Infect. Dis. 43:99-102
30. Chessman D, Kostenko L, Lethborg T, et al. 2008. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28:822-32
31. Illing PT, Vivian JP, Dudek NL, et al. 2012. Immune self-reactivity triggered by drug-modified HLApeptide repertoire. Nature 486:554-58
32. Ostrov DA, Grant BJ, Pompeu YA, et al. 2012. Drug hypersensitivity caused by alteration of the MHCpresented self-peptide repertoire. Proc. Natl. Acad. Sci. USA 109:9959-64
33. Norcross MA, Luo S, Lu L, et al. 2012. Abacavir induces loading of novel self-peptides intoHLA-B57:01: an autoimmune model for HLA-Associated drug hypersensitivity. AIDS 26:F21-29
34. Amir AL, D'Orsogna LJ, Roelen DL, et al. 2010. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 115:3146-57
35. Amir AL, van der Steen DM, Hagedoorn RS, et al. 2011. Allo-HLA-reactiveTcells inducing graft-versushost disease are single peptide specific. Blood 118:6733-42
36. Burrows SR, Khanna R, Burrows JM, Moss DJ. 1994. An alloresponse in humans is dominated by cytotoxic Tlymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graftversus-host disease. J. Exp. Med. 179:1155-61
37. Gamadia LE, Remmerswaal EB, Surachno S, et al. 2004. Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules. Transplantation 77:1879-85
38. Koelle DM, ChenHB, McClurkan CM, Petersdorf EW. 2002. Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles. Blood 99:3844-47
39. Deckers JGM, Boonstra JG, Van Der Kooij SW, et al. 1997. Tissue-specific characteristics of cytotoxic graft-infiltrating T cells during renal allograft rejection. Transplantation 64:178-81
40. D'Orsogna LJ, Roelen DL, Doxiadis II, Claas FH. 2010. Alloreactivity from human viral specificmemory T-cells. Transpl. Immunol. 23:149-55
41. D'Orsogna LJ, Roelen DL, van der Meer-Prins EM, et al. 2011. Tissue specificity of cross-reactive allogeneic responses by EBV EBNA3A-specific memory T cells. Transplantation 91:494-500
42. Zhu J, Peng T, Johnston C, et al. 2013. Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature 497:494-97
43. Kaniwa N, Saito Y, Aihara M, et al. 2010. HLA-B1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51:2461-65
44. Sun D, Yu CH, Liu ZS, et al. 2014. Association of HLA-B1502 and 1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. J. Huazhong Univ. Sci. Technol. 34:146-50
45. Hung SI, Chung WH, Liu ZS, et al. 2010. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11:349-56
46. WuY, Wang XQ, Gan ZJ, Fan M. 2012. HLA-B1502 allele screening: determination of carbamazepineinduced cutaneous reactions. Epilepsia 53:929-30
47. Ozeki T, Mushiroda T, Yowang A, et al. 2011. Genome-wide association study identifies HLA-A3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20:1034-41
48. Grover S, Kukreti R. 2014. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-Analysis. Pharmacogenet. Genomics 24:94-112
49. Genin E, Chen DP, Hung SI, et al. 2014. HLA-A31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-Analysis. Pharmacogenomics J. 14:281-88
50. Amstutz U, Ross CJ, Castro-Pastrana LI, et al. 2013. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin. Pharmacol. Ther. 94:142-49
51. Niihara H, Kakamu T, Fujita Y, et al. 2011. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J. Dermatol. 39:594-601
52. LichtenfelsM, Farrell J, OgeseMO, et al. 2014. HLA restriction of carbamazepine-specific T-cell clones from an HLA-A31:01-positive hypersensitive patient. Chem. Res. Toxicol. 27:175-77
53. Ko TM, Chung WH, Wei CY, et al. 2011. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 128:1277-78
54. Wei CY, Chung WH, Huang HW, et al. 2012. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 129:1562-69
55. Phillips E, Bartlett JA, Sanne I, et al. 2013. Associations between HLA-DRB10102, HLA-B5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J. Acquir. Immune Defic. Syndr. 62:e55-57
56. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. 2009. HLA-B3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics 19:139-46
57. Gatanaga H, Yazaki H, Tanuma J, et al. 2007. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 21:264-65
58. Littera R, Carcassi C, Masala A, et al. 2006. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20:1621-26
59. Carr DF, Chaponda M, Jorgensen AL, et al. 2013. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin. Infect. Dis. 56:1330-39
60. Gao S, Gui XE, Liang K, et al. 2012. HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients. AIDS Res. Hum. Retroviruses 28:540-43
61. Likanonsakul S, Rattanatham T, Feangvad S, et al. 2009. HLA-Cw04 allele associated with nevirapineinduced rash in HIV-infected Thai patients. AIDS Res. Ther. 6:22
62. Keane NM, Pavlos RK, McKinnon E, et al. 2014. HLA class I restricted CD8+ and class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity. AIDS 28:1891-901
63. PersaudD, Gay H, Ziemniak C, et al. 2013. Absence of detectableHIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369:1828-35
64. Persaud D, Deveikis A, Gay H, et al. 2014. Very early combination antiretroviral therapy in perinatal HIV infection: two case studies. Presented at Conf. Retroviruses and Opportunistic Infections, Boston
65. Ciccacci C, Di Fusco D, Marazzi MC, et al. 2013. Association between CYP2B6 polymorphisms and nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur. J. Clin. Pharmacol. 69:1909-16
66. Dickinson L, Chaponda M, Carr DF, et al. 2014. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. Antimicrob. Agents Chemother. 58:706-12
67. Lehr T, Yuan J, Hall D, et al. 2011. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenet. Genomics 21:721-30
68. LucenaMI, Molokhia M, Shen Y, et al. 2011. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141:338-47
69. StevensR, CoatesE, Street J, et al. 2013. Comprehensive evaluation of two HLA-B17monoclonal antibodies for flow cytometry-based HLA-B57/B58 screening prior to abacavir prescription. Int. J. Immunogenet. 40:311-15
70. Kaniwa N, Saito Y, Aihara M, et al. 2008. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9:1617-22
71. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. 2009. Strong association between HLA-B5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19:704-9
72. Emmerson BT, Hazelton RA, Frazer IH. 1988. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum. 31:436-40
73. Yun J, Mattsson J, Schnyder K, et al. 2013. Allopurinol hypersensitivity is primarily mediated by dosedependent oxypurinol-specific T cell response. Clin. Exp. Allergy 43:1246-55
74. Day RO, Graham GG, Hicks M, et al. 2007. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin. Pharmacokinet. 46:623-44
75. Braden GL, Warzynski MJ, GolightlyM, BallowM. 1994. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin. Immunol. Immunopathol. 70:145-51
76. Narzi D, Becker CM, Fiorillo MT, et al. 2012. Dynamical characterization of two differentially disease associated MHC class I proteins in complex with viral and self-peptides. J. Mol. Biol. 415:429-42
77. Yun J, Marcaida MJ, Eriksson KK, et al. 2014. Oxypurinol directly and immediately activates the drugspecific T cells via the preferential use of HLA-B58:01. J. Immunol. 192:2984-93
78. WhiteK, Gaudieri S, Phillips E. 2013. HLA and pharmacogenomics of drug hypersensitivity. In Handbook of Pharmagenomics and Stratified Medicine, ed. S Padmanabhan, 1:437-59. London: Academic, Elsevier
79. Chung WH, Chang WC, Lee YS et al. 2014. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312:525-34
80. ChungWH, ChangWC, Stocker SL et al. 2014. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann. Rheum. Dis. In press